A Phase II Study of Lenvatinib Monotherapy as Second-Line Treatment in Unresectable Biliary Tract Cancer: Primary Analysis Results

被引：0

作者：

Ikeda, Masafumi ^{[1
]}

Sasaki, Takashi ^{[2
]}

Morizane, Chigusa ^{[3
]}

Mizuno, Nobumasa ^{[4
]}

Nagashima, Fumio ^{[5
]}

Shimizu, Satoshi ^{[6
]}

Hayata, Nozomi ^{[7
]}

Ikezawa, Hiroki ^{[7
]}

Suzuki, Takuya ^{[7
]}

Nakajima, Ryo ^{[7
]}

Dutcus, Corina E. ^{[8
]}

Bower, John ^{[9
]}

Ueno, Makoto ^{[10
]}

机构：

[1] Hosp East, Natl Canc Ctr, Kashiwa, Chiba, Japan

[2] JFCR, Canc Inst Hosp, Tokyo, Japan

[3] Natl Canc Ctr, Tokyo, Japan

[4] Aichi Canc Ctr Hosp, Nagoya, Aichi, Japan

[5] Kyorin Univ, Tokyo, Japan

[6] Saitama Canc Ctr, Saitama, Japan

[7] Eisai & Co Ltd, Tokyo, Japan

[8] Eisai Inc, Woodcliff Lake, NJ USA

[9] Eisai Australia Pty Ltd, Melbourne, Vic, Australia

[10] Kanagawa Canc Ctr Hosp, Yokohama, Kanagawa, Japan

来源：

关键词：

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

151

引用

页码：115 / 115

页数：1